Why the study?
Soluble suppression of tumorigenicity-2 (sST-2) has been linked to the development of AF, but its relationship with AF recurrence after catheter ablation required evaluation.
Are high baseline serum sST-2 levels associated with an increased risk of atrial fibrillation recurrence after catheter ablation?
Are high baseline serum sST-2 levels associated with an increased risk of atrial fibrillation recurrence after catheter ablation?
Elevated baseline serum sST-2 levels may serve as a biomarker for predicting an increased risk of atrial fibrillation recurrence following catheter ablation.
Elevated baseline sST-2 may flag higher AF recurrence risk after ablation; leaves open its value as a predictive biomarker pending prospective validation.
Soluble suppression of tumorigenicity-2 (sST-2), a marker of myocardial fibrosis and remodeling, has been related to the development of atrial fibrillation (AF). The aim of this meta-analysis was to evaluate the relationship between baseline serum sST-2 levels and the risk of AF recurrence after ablation. Relevant observational studies were retrieved from PubMed, Web of Science, Embase, Wanfang and China National Knowledge Infrastructure (CNKI). A random-effects model was used to combine the data, accounting for between-study heterogeneity. Fourteen prospective cohorts were included. Pooled results showed higher sST-2 levels before ablation in patients with AF recurrence compared to those without AF recurrence (standardized mean difference = 1.15, 95% confidence interval [CI] = 0.67 to 1.63, P < 0.001; I2 = 92%). Meta-regression analysis suggested that the proportion of patients with paroxysmal AF (PaAF) was positively related to the difference in serum sST-2 levels between patients with and without AF recurrence (coefficient = 0.033, P < 0.001). Subgroup analysis showed a more remarkable difference in serum sST-2 levels between patients with and without AF recurrence in studies where PaAF was ≥ 60% compared to those where it was < 60% (P = 0.007). Further analyses showed that high sST-2 levels before ablation were associated with an increased risk of AF recurrence (odds ratio [OR] per 1 ng/mL increment of sST-2 =1.05, OR for high versus low sST-2 = 1.73, both P values < 0.05). In conclusion, high sST-2 baseline levels may be associated with an increased risk of AF recurrence after catheter ablation.
No takes yet. Share an insight, caveat, or question.
Shi et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: